Who Paid My Doc
George MacRis
Undersea and Hyperbaric Medicine Dededo, GU Medical Doctor
NPI 1336445055 CMS profile 600544
2214 Army Dr, Dededo, GU 96929
General payments
$282
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, George MacRis of Dededo, GU is reported in the CMS Open Payments database as having received $282 across 13 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 36th percentile of Undersea and Hyperbaric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $129 | 6 | |
| 2022 | General | $119 | 5 | |
| 2021 | General | $34 | 2 |
Beside peers
- George MacRis
- Undersea and Hyperbaric Medicine median
- Middle half of Undersea and Hyperbaric Medicine
- National median
In program year 2025, general payments to George MacRis were reported at $0. Among 121 Undersea and Hyperbaric Medicine profiles paid that year, the median was $208 and the middle half received between $52 and $518.
Show as a table
| Year | George MacRis | Undersea and Hyperbaric Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $201 | $85–$538 | $163 |
| 2020 | $0 | $84 | $31–$222 | $114 |
| 2021 | $34 | $138 | $52–$383 | $132 |
| 2022 | $119 | $135 | $51–$385 | $149 |
| 2023 | $129 | $143 | $75–$442 | $160 |
| 2024 | $0 | $178 | $80–$442 | $164 |
| 2025 | $0 | $208 | $52–$518 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 119 drugsPart D claims
6,905
Drug cost
$295,084
Branded share of claims
15.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Xarelto Rivaroxaban | Brand | 35 | $53,402 | |
| Eliquis Apixaban | Brand | 41 | $52,754 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 16 | $26,164 | |
| Jardiance Empagliflozin | Brand | 19 | $23,477 | |
| Vraylar Cariprazine Hcl | Brand | 14 | $20,363 | |
| Tradjenta Linagliptin | Brand | 13 | $12,627 | |
| Advair Hfa Fluticasone Propion/Salmeterol | Brand | 14 | $9,399 | |
| Toujeo Solostar Insulin Glargine,hum.Rec.Anlog | Brand | 19 | $8,136 | |
| Rosuvastatin Calcium | Generic | 646 | $5,723 | |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | Brand | 21 | $5,645 |
The 10 drugs with the highest cost, of 119 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 17 billing codesPaid by Medicare
$15,681
Medicare patients
52
Services billed
207
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 48% | |
| COPD | 27% | |
| Depression | 27% | |
| Diabetes | 21% | |
| Ischemic heart disease | 21% | |
| Chronic kidney disease | 21% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
13 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Undersea and Hyperbaric Medicine in Guam
Related records
Undersea and Hyperbaric Medicine in Guam
Practitioners in the same specialty and state, ranked by reported value.
All Undersea and Hyperbaric Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Guam
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.